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Disclaimer: This guideline is designed primarily as an educational resource for health care providers to help them provide quality
medicalgeneticservices.Adherencetothisguidelinedoesnotnecessarilyassureasuccessfulmedicaloutcome.Thisguidelineshould
not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed
toobtainingthesameresults.Indeterminingtheproprietyofanyspecificprocedureortest,thegeneticistshouldapplyhisorherown
professional judgment to the specific clinical circumstances presented by the individual patient or specimen. It may be prudent,
however, to document in the patient’s record the rationale for any significant deviation from this guideline.
The autosomal recessive disorder proximal spinal muscular
atrophy (SMA, MIM #253300) is a severe neuromuscular dis-
ease characterized by degeneration of alpha motor neurons in
the spinal cord, which results in progressive proximal muscle
weaknessandparalysis.SMAisthesecondmostcommonfatal
autosomal recessive disorder after cystic fibrosis, with an esti-
mated prevalence of 1 in 10,000 live births and a carrier fre-
quencyof1/40–1/60.ChildhoodSMAissubdividedintothree
clinical groups on the basis of age of onset and clinical course:
type I SMA (Werdnig-Hoffmann) is characterized by severe,
generalized muscle weakness and hypotonia at birth or within
the first 3 months. Death from respiratory failure usually oc-
curswithinthefirst2years.ChildrenwithtypeIIareabletosit,
although they cannot stand or walk unaided and survive be-
yond 4 years. Type III SMA (Kugelberg-Welander) is a milder
form, with onset during infancy or youth: patients learn to
walk unaided.
The survival motor neuron (SMN) gene comprises nine ex-
ons and has been shown to be the primary SMA determining
gene.TwoalmostidenticalSMNgenesarepresenton5q13:the
telomericorSMN1gene,whichistheSMA-determininggene,
and the centromeric or SMN2 gene. The SMN1 gene exon 7 is
homozygously absent in approximately 95% of affected pa-
tients,withfewexceptions,theremainderareheterozygousfor
the exon 7 deletion and a small more subtle mutation in the
other allele (compound heterozygotes). Although abnormali-
ties of the SMN1 gene are observed in the majority of patients,
no phenotype–genotype correlation was observed because
SMN1exon7isabsentinthemajorityofpatientsindependent
ofthetypeofSMA.Thisisbecauseroutinediagnosticmethods
do not distinguish between a deletion of SMN1 and a conver-
sion event whereby SMN1 is replaced by a copy of SMN2.
There have now been several studies that have shown that the
SMN2 copy number influences the severity of the disease. The
copy number varies from zero to three copies in the normal
population, with approximately 15% of normal individuals
having no SMN2. However, milder patients with type II or III
have been shown to have more copies of SMN2 than do type I
patients.IthasbeenproposedthattheextraSMN2inthemore
mildly affected patients arise through gene conversions,
wherebytheSMN2geneiscopiedeitherpartiallyortotallyinto
the telomeric locus.
FivebasepairchangesexistbetweenSMN1andSMN2tran-
scripts, and none of these differences change amino acids. Be-
cause virtually all SMA individuals have at least one SMN2
genecopy,itwasinitiallynotunderstoodwhyindividualswith
SMN1 mutations have a SMA phenotype. It has now been
shown that the SMN1 gene produces predominately full-
length transcript, whereas the SMN2 copy produces predomi-
nately an alternatively transcribed (exon 7 deleted) product.
The inclusion of exon 7 in SMN1 transcripts and exclusion of
this exon in SMN2 transcripts is caused by a single nucleotide
differenceat6inSMNexon7.AlthoughtheCtoTchangein
SMN2exon7doesnotchangeanaminoacid,itdoesdisruptan
exonic splicing enhancer that results in the majority of SMN2
transcripts lacking exon 7. Therefore, SMA arises because the
SMN2 gene cannot fully compensate for the lack of SMN1
expression when SMN1 is mutated. However, the small
amount of full length transcripts generated by SMN2 is able to
produceamildertypeIIorIIIphenotypewhenthecopynum-
ber of SMN2 is increased.
The molecular diagnosis of the SMA consists of the detec-
tion of the absence of exon 7 of the SMN1 gene. The homozy-
gousabsenceofdetectableSMN1inSMApatientsisbeingused
as a powerful diagnostic test for SMA. Although the targeted
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95%inidentifyingaffectedhomozygotes,itcannotdetectSMA
carriers who have heterozygous deletions of SMN1. Rather,
SMN1 gene dosage analysis is required to detect carriers and is
highlyaccuratewhenperformedinanexperiencedlaboratory.
Because SMA is one of the most common lethal genetic disor-
ders, with a carrier frequency of 1/40–1/60, direct carrier dos-
age testing has been beneficial to many families with affected
children. A number of quantitative polymerase chain reaction
assays have been used for the identification of SMA carriers.
There are two limitations of the carrier test. First, approxi-
mately2%ofSMAcasesariseastheresultofdenovomutation
events, which is high when compared with most autosomal
recessive disorders. The high rate of de novo mutations in
SMN1 may account for the high carrier frequency in the gen-
eral population despite the genetic lethality of the type I dis-
ease. The large number of repeated sequences around the
SMN1andSMN2locuslikelypredisposethisregiontounequal
crossoversandrecombinationeventsandresultsinthehighde
novo mutation rate. The de novo mutations have been shown
to occur primarily during paternal meiosis. Second, the copy
number of SMN1 can vary on a chromosome; we have ob-
served that approximately 5% of the normal population pos-
sess three copies of SMN1. It is therefore possible for a carrier
to possess one chromosome with two copies and a second
chromosomewithzerocopies.ThefindingoftwoSMN1genes
on a single chromosome has serious genetic counseling impli-
cations, because a carrier with two SMN1 genes on one chro-
mosome and a SMN1 deletion on the other chromosome will
have the same dosage result as a noncarrier with one SMN1
gene on each chromosome 5. Thus, the finding of normal two
SMN1 copy dosage significantly reduces the risk of being a
carrier; however, there is still a residual risk of being a carrier
andsubsequentlyasmallrecurrenceriskoffutureaffectedoff-
spring for individuals with 2 SMN1 gene copies. Risk assess-
ment calculations using Bayesian analysis are essential for the
proper genetic counseling of SMA families.
Currently,onlyindividualswithafamilyhistoryofSMAare
routinely being offered carrier testing. However, more broad-
based population carrier screening is currently recommended
for a number of other genetic disorders with similar carrier
frequencies. The prototype for heterozygote screening was
testing for Tay-Sachs disease in the Ashkenazi Jewish popula-
tion, where carrier testing has been offered since 1969. Carrier
screening, followed by prenatal diagnosis when indicated, has
resulted in a dramatic decrease in the incidence of Tay-Sachs
disease in the Jewish population. It is generally accepted that
thefollowingcriteriashouldbemetforascreeningprogramto
be successful: (1) disorder is clinically severe, (2) high fre-
quency of carriers in the screened population, (3) availability
ofareliabletestwithahighspecificityandsensitivity,(4)avail-
ability of prenatal diagnosis, and (5) access to genetic counsel-
ing. SMA fits the criteria for population-based genetic screen-
ing.Carrierscreeningisrecommendedupontheavailabilityof
educational material that can be utilized by patients and pro-
viders.
The goal of population based SMA carrier screening is to
identify couples at risk for having a child with SMA. Precon-
ceptioncarrierscreeningallowscarriercouplestoconsiderthe
fullest range of reproductive options. The choice to have a
SMA carrier test should be made by an informed decision.
Educational brochures are available and provide information
about SMA and the inheritance patterns. It is important for
couples to understand the dosage testing. Because, SMA is the
result of a common single deletion event in 95% of the cases,
the carrier test is very sensitive (90% detection rate). How-
ever, the molecular testing does not identify all carriers and
therefore false-negatives can occur. Approximately 5% of af-
fected patients are compound heterozygotes, exhibiting a
deletion and a point mutation. The dosage testing does not
identify such point mutation carriers. It is well known that a
false-negative result in SMA carriers occurs when the carrier
hastwoSMN1genesincisontheonechromosome5.Further,
approximately 2% of affected individuals have a de novo mu-
tation. Therefore, genetic counseling addressing specifically
the possibility of false-negative results must be provided for
individuals choosing carrier testing.
Recommendations
1. BecauseSMAispresentinallpopulations,carriertestingshould
be offered to all couples regardless of race or ethnicity. Ideally,
thetestingshouldbeofferedbeforeconceptionorearlyinpreg-
nancy. The primary goal is to allow carriers to make informed
reproductive choices.
2. Formal genetic counseling services must be made available to
anyone requesting this testing. It is important that all individu-
als undergoing testing understand that a carrier is a healthy
individual who is not at risk of developing the disease but has a
riskofpassingthegenemutationtohis/heroffspring.Counsel-
ing must also include a description of the disorder, including
the range of severity. Educational material about SMA should
bemadeavailabletoallcouplespreferablyinthepreconception
period. It is imperative that individuals understand the limita-
tions of the molecular testing.
3. All identified carriers should be referred for follow-up genetic
counseling for a discussion of risk to the fetus or future preg-
nancies. Prenatal and preimplantation diagnosis should be of-
fered.
4. A negative screening test for one or both partners reduces but
does not eliminate the possibility of an affected offspring, be-
cause the test sensitivity is 100% (90% detection rate). It is
important that couples also recognize that the carrier testing
does not provide genotype/phenotype information. Type I
SMA occurs in approximately 70% of the cases, whereas the
milder types II and III account for the remaining 30% of the
cases.
5. As is true for all carrier screening programs, the testing is vol-
untary. Informed consent and the usual caveats must be ad-
dressed including assurance of confidentiality, paternity issues,
discrimination, self-esteem, and cost.
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